Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Open-label, Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

NCT05665348 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT05665348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Open-label, Phase II-III Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 2/3
Overall status
Completed
Start date
March 9, 2023
Completion date
May 12, 2025
Enrollment
229 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma, metastatic cancer, metastatic tumor